Haemostatic alterations and management of haemostasis in patients with cirrhosis
- PMID: 35589251
- DOI: 10.1016/j.jhep.2021.11.004
Haemostatic alterations and management of haemostasis in patients with cirrhosis
Abstract
Patients with cirrhosis frequently acquire complex changes in their haemostatic system including a decreased platelet count and decreased levels of various haemostatic proteins. Although historically patients with cirrhosis were thought to have a haemostasis-related bleeding tendency, it is now widely accepted that the haemostatic system of patients with cirrhosis remains in balance as a result of simultaneous changes in pro- and anti-haemostatic systems. The concept of rebalanced haemostasis has led to changes in clinical management, although firm evidence from well-designed clinical studies is largely lacking. For example, many invasive procedures in patients with cirrhosis and a prolonged prothrombin time are now performed without prophylaxis with fresh frozen plasma. Conversely, clinicians have become more aware of the need for anti-thrombotic therapy, even in those patients with abnormal routine coagulation tests. This paper will outline recent advances in pathogenesis, prevention and treatment of both bleeding and thrombotic complications in patients with cirrhosis. Among other topics, we will discuss the haemostatic status of acutely ill patients with cirrhosis, the various causes of bleeding in patients with cirrhosis, and how best to prevent or treat bleeding. In addition, we will discuss the hypercoagulable features of patients with cirrhosis, new insights into the pathogenesis of portal vein thrombosis, and how best to prevent or treat thromboses.
Keywords: bleeding; coagulation; fresh frozen plasma; liver disease; platelets; portal vein thrombosis; thrombosis; variceal bleeding.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest TL has no conflicts of interest to report. NMI reports education grant support from Dova. SHC reports research sponsored trials (NASH, PBC, PSC) from Gilead, Madrigal, BMS, GenFit, Zydus, Galectin, Akero, Galmed, and Inventiva; Royalty for device from Avanos; Honoraria for Lectures from Houston Methodist, University Washington, Thomas Jefferson University; Grant support for Coagulation in Liver Disease meeting from Shionogi and Dova. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.J Hepatol. 2023 Feb;78(2):e57-e59. doi: 10.1016/j.jhep.2022.11.001. Epub 2022 Nov 9. J Hepatol. 2023. PMID: 36370953 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical